TL;DR
A CNTF-peptide with an adamantyl bolt-on. Built neurons in Alzheimer's mice. No human trial ever.
What is it? An 8-amino-acid CNTF fragment conjugated to an adamantyl group for brain penetration. Designed by Khalid Iqbal's lab at NYSIBR (Staten Island). Built as a CNTF mimetic that crosses the blood-brain barrier.
What does it do? Raises hippocampal BDNF, drives adult neurogenesis in the dentate gyrus and subventricular zone, inhibits GSK-3β and tau hyperphosphorylation, and improves spatial and recognition memory in transgenic Alzheimer's mouse models.
Does the evidence hold up? Fifteen-plus Iqbal-lab papers (2010–2023) across sporadic AD, 3xTg and Tg2576 familial AD, Down syndrome, and aging rodent models. No human trials. No IND filed as of April 2026. Independent replication outside NYSIBR is limited.
Who uses it? Rodent Alzheimer's and neurogenesis labs. A small nootropic-focused self-experimenter community orders research-chemical p021 despite zero human data.
Bottom line? Clean mouse neurogenesis story from one lab. Fifteen years in, still no human trial.
What It Is
P21 (also designated P021) is a small adamantyl-conjugated peptidergic compound derived from the active domain of ciliary neurotrophic factor (CNTF). The design approach — developed by Dr. Khalid Iqbal and colleagues at the New York State Institute for Basic Research in Developmental Disabilities (NYSIBR, Staten Island) over the period 2010 to 2023 — sought to overcome the three principal limitations of native CNTF as a therapeutic: (1) extremely short plasma half-life, (2) inability to cross the blood-brain barrier, and (3) side-effect profile (weight loss, inflammation) that derailed the ciliary neurotrophic factor Phase 3 program in ALS in the 1990s.
Structurally, P21 is an eight-amino-acid peptide fragment mapped to CNTF "peptide 6" (amino acids 148–151 of CNTF) with an adamantane (tricyclo[3.3.1.1³,⁷]decane) group conjugated via a flexible linker. The adamantyl modification — borrowed from the CNS-penetrant pharmacology of memantine and amantadine — confers three properties: blood-brain barrier penetration, resistance to peptidase degradation (extending plasma half-life from minutes to hours), and oral bioavailability. The molecule is formally neither peptide nor small molecule but a peptidergic hybrid, sometimes described in the Iqbal-lab literature as a "peptide mimetic" or "pharmacological peptide."
The scientific hypothesis motivating P21 is that CNTF-pathway activation drives two neurotrophic outputs with direct relevance to cognitive aging and Alzheimer's disease: (1) upregulation of brain-derived neurotrophic factor (BDNF), the master growth factor for synaptic plasticity and neuronal survival, and (2) activation of adult hippocampal neurogenesis — the creation of new dentate gyrus granule neurons that functionally integrate into existing memory circuits. Adult neurogenesis is substantially reduced in aged and Alzheimer's brains, and restoring it is one of the most mechanistically rational interventions for age-related cognitive decline.
P21 has accumulated a 15+ paper preclinical evidence base from the Iqbal lab in rodent models of sporadic and familial Alzheimer's disease (3xTg-AD, APP/PS1, Tg2576), Down syndrome cognitive impairment (Ts65Dn), and normal aging. The compound improves spatial memory (Morris water maze), recognition memory, synaptic density markers (synaptophysin, PSD-95, MAP-2), and reduces tau hyperphosphorylation. Pharmacokinetic studies have been published in mice and cynomolgus monkeys. Despite this consistent preclinical signal, P21 has never entered human clinical trials — no IND, no Phase 1, no sponsor has advanced the molecule through the regulatory pathway as of April 2026. It remains one of the most mechanistically promising neurogenesis-promoting research peptides with a complete absence of human data.
Mechanism of Action
P21's proposed mechanism centers on CNTF-pathway-mediated BDNF elevation and downstream neurogenic / anti-tau effects.
- CNTF receptor pathway mimicry — P21 is hypothesized to activate the tripartite CNTF receptor (CNTFR-α / LIFR / gp130) or a subset of its downstream signaling cascade, engaging JAK/STAT3 and RAS/MAPK pathways that drive neurotrophic transcriptional programs. Unlike native CNTF it does not produce the systemic-inflammatory or weight-loss side effects that halted the CNTF Phase 3 ALS program.
- BDNF upregulation — The primary biochemical readout across P21's preclinical literature. Hippocampal BDNF protein levels increase 30–60% following chronic P21 treatment in transgenic AD and aged animals. BDNF is the master growth factor for synaptic plasticity, neuronal survival, and long-term potentiation (LTP) — the cellular correlate of learning.
- Adult hippocampal neurogenesis — BrdU and doublecortin-labeling studies show significant (2–3 fold) increases in proliferating neural progenitor cells in the subgranular zone of the dentate gyrus in treated animals. Critically, these new neurons survive, differentiate into mature granule cells, and integrate into existing hippocampal circuits — not merely proliferate.
- GSK-3β inhibition and tau dephosphorylation — P21 reduces hyperphosphorylation of tau protein at AD-relevant epitopes (Thr181, Ser202, Ser396, Ser404) via inhibition of glycogen synthase kinase-3β (GSK-3β) and related tau kinases. This decreases neurofibrillary-tangle-type pathology in tau-transgenic models.
- Synaptic plasticity and LTP enhancement — Electrophysiological recordings from P21-treated hippocampal slices show enhanced long-term potentiation and restored paired-pulse facilitation in AD models — the functional correlate of the structural/molecular changes.
- Amyloid pathology modulation — In APP/PS1 and 3xTg-AD mice, chronic P21 treatment reduces soluble and insoluble Aβ levels, likely via indirect mechanisms (neurotrophic support, microglial phenotype modulation) rather than direct secretase inhibition.
- PI3K/Akt anti-apoptotic signaling — P21 engages the PI3K/Akt pathway downstream of BDNF/TrkB, supporting neuronal survival under oxidative and excitotoxic stress.
- Blood-brain barrier penetration — Adamantyl modification confers lipophilicity and passive diffusion across the BBB. Pharmacokinetic studies in mice and monkeys show measurable brain tissue levels after oral, subcutaneous, and intranasal dosing.
- Microglial phenotype modulation — Reduces pro-inflammatory microglial activation while preserving phagocytic function, consistent with the broader anti-neuroinflammatory signal seen with several BDNF-upregulating interventions.
- Sparing of CNTF systemic side-effect profile — Unlike native CNTF, P21 does not produce the cachexia, cytokine cascade, or anti-drug antibody response that halted the CNTF Phase 3 ALS trial program. This "clean" side-effect profile is the central advantage that motivated the Iqbal-lab development program.
What the Research Shows
P21's preclinical literature is mechanistically consistent across rodent models of sporadic AD, familial AD, Down syndrome cognitive impairment, and normal aging.
- Original design and in vitro characterization (Li et al., FEBS Lett 2010; PMID 20638986) — The foundational P21 paper. Adamantyl-peptide engineering rationale, in vitro BBB permeability, neurogenesis signal in neural progenitor cultures, and initial rodent pharmacodynamic data.
- Sporadic AD rat model (Bolognin et al., Acta Neuropathol 2012; PMID 22454023) — Intracerebroventricular streptozotocin-induced sporadic AD rat model. P21 rescued cognitive impairment on Morris water maze and novel object recognition; preserved synaptic protein expression.
- 3xTg-AD familial AD model chronic oral treatment (Kazim et al., Neurobiol Dis 2014; PMID 25046994) — Central Alzheimer's efficacy paper. Chronic oral P21 in drinking water in 3xTg-AD mice prevented cognitive decline, reduced tau pathology, increased neurogenesis, and improved synaptic density. Both preventive (pre-pathology) and therapeutic (post-pathology) arms showed benefit.
- Mechanistic review (Kazim & Iqbal, Mol Neurodegener 2016; PMID 27400670) — Authoritative Iqbal-lab synthesis of the neurotrophic small-molecule-mimetic program.
- Pharmacokinetic and safety characterization (Blanchard et al., Drug Des Devel Ther 2014; PMID 25028537) — PK and safety profile of P021 in mice and cynomolgus monkeys. Supports the oral/SubQ dosing and BBB-penetration claims; no observable toxicity at therapeutic doses.
- Down syndrome cognitive impairment (Kazim et al., Neurobiol Dis 2017; PMID 28823930) — P21 in Ts65Dn Down syndrome mouse model; improved cognition and increased dentate gyrus neurogenesis — relevant to trisomy-21 cognitive impairment.
- Tg2576 familial AD chronic oral (Baazaoui & Iqbal, J Alzheimers Dis 2017; PMID 28527206) — Extended the 3xTg-AD data to a second AD transgenic line, strengthening model-generalization evidence.
- Aged-rat normal-aging study (Baazaoui & Iqbal, Neuropharmacology 2017) — P21 restored hippocampal neurogenesis and cognitive function in aged rats — extending the therapeutic target beyond Alzheimer's to "normal" age-related cognitive decline.
- Perinatal brain injury (Kazim et al., Brain Behav Immun 2021) — Preclinical extension into perinatal hypoxic-ischemic injury models.
- APP/PS1 combined-pathology AD model — Chronic P21 reduced Aβ plaque load and tau hyperphosphorylation; improved Y-maze alternation and contextual fear conditioning.
- Stereotaxic injection intrahippocampal (Li, Kazim, Iqbal) — Direct hippocampal administration demonstrated proof-of-target engagement.
Critical Research Limitations
P21 has never entered human clinical trials. No IND application has been filed as of April 2026. The preclinical evidence base is strong but geographically concentrated — the overwhelming majority of P21 / P021 publications originate from the single NYSIBR laboratory of Dr. Khalid Iqbal. Independent replication outside the originating lab is limited. Translation from transgenic mouse models to human AD has been a graveyard for neuroprotective compounds across the past three decades (failed BACE inhibitors, γ-secretase modulators, tarenflurbil, solanezumab, verubecestat, and many more). Strong preclinical neurogenesis data do not predict human clinical success. Anyone using P21 off-label is effectively conducting a solo Phase 1 study with no dose-ranging, no PK validation, and no safety signal surveillance infrastructure.
Human Data
There are no published human clinical trials of P21 as of April 2026. Despite a mechanistically coherent and reproducible preclinical evidence base spanning over a decade, P21 has not advanced into human testing. The evidence-base summary for "human data" is therefore limited to what is known by extrapolation:
- No IND application — No Investigational New Drug application has been filed with the FDA by any sponsor as of the current database check.
- No Phase 1 safety data — Human pharmacokinetics, maximum tolerated dose, and adverse-event profile are entirely unknown.
- No community pharmacovigilance infrastructure — A small off-label user community reports anecdotal use through research-chemical channels. These reports are not collected systematically; no case series has been published; there is no dose-response or adverse-event tracking.
- Pharmacokinetic extrapolation — The published mouse and cynomolgus PK data support oral bioavailability, BBB penetration, and hours-scale plasma half-life. These allometric scalings are the basis of community human dosing estimates.
- Structural similarity to validated CNS-penetrant adamantyl drugs — The adamantyl moiety is used in approved CNS drugs (memantine, amantadine), which provides indirect class-precedent confidence in CNS penetration but does not establish safety of the P21 scaffold specifically.
- CNTF parent-molecule context — Native CNTF was advanced to Phase 3 for ALS in the 1990s and halted for tolerability issues. P21's design explicitly sought to escape this side-effect profile by using only the "active peptide 6" fragment; preclinical data supports this. Whether the escape holds in humans is unknown.
- Mechanistic target class precedent (BDNF-elevating interventions) — Exercise, SSRIs, ketamine, electroconvulsive therapy, and other validated BDNF-elevating interventions have mixed safety signals at the class level; there is no sustained adverse pattern that would predict P21-specific liability.
- Neurogenesis-target class precedent — Few approved drugs directly promote adult neurogenesis; validated neurogenesis promoters in humans remain an open clinical frontier.
Summary: P21 is a preclinical candidate. There is no human evidence base. Users are effectively solo Phase 1 subjects making dose and safety decisions from extrapolation.
Dosing from the Literature
All published dosing is from animal studies in the Iqbal-lab protocol set. Human dosing is extrapolated by allometric scaling from the animal data; the following values should be treated as research-community heuristics, not validated clinical dosing.
| Protocol | Dose | Route | Notes |
|---|
| Mouse chronic oral (3xTg-AD, Tg2576) | ~60 nmol / mL drinking water | Oral ad libitum | Translates to ~40 mg/kg/day at ~3 mL/day consumption in 25 g mouse. |
| Mouse SubQ | 100–300 µg/day | SubQ | Alternative route; chronic (months). |
| Mouse intranasal | 60–100 µg/day | Intranasal | Direct CNS delivery; 10 µL drops both nostrils. |
| Rat ICV stereotactic | ~40 nmol/h via mini-pump | ICV | Proof-of-target; not translatable. |
| Human extrapolated (community) | 100–300 µg | SubQ or intranasal, daily | Allometric scaling; NOT validated in humans. No PK, no MTD. |
| Course duration | — | — | Preclinical efficacy required chronic dosing (weeks-months); community protocols often 8–12 weeks. |
Neurogenesis Takes Time
Adult hippocampal neurogenesis is a slow process. Neural progenitor cells must proliferate, migrate into the granule cell layer, differentiate into mature dentate gyrus granule cells, and integrate into existing circuits — a sequence that requires 4–8 weeks in rodent models. Acute effects are not the expected signature of P21. Any behavioral response observed within the first week of use is more likely attributable to BDNF elevation or non-specific effects than to accumulated neurogenesis.
Dosing Disclaimer
P21 has never been administered to humans in any published study. The community-extrapolated dosing ranges above are not validated by pharmacokinetic data, MTD studies, or phase-1 safety characterization. Anyone using P21 off-label is effectively operating as a solo human Phase 1 investigator. This is an unusual risk posture even among research peptides.
Reconstitution & Storage
Research-grade P21 is supplied as lyophilized powder, typically 5 or 10 mg per vial from research-chemical vendors. Purity verification by HPLC and mass spectrometry is particularly important for this compound given the adamantyl-linker modification — batch-to-batch variability in conjugation efficiency has been noted among suppliers.
| Vial Size | BAC Water | Concentration | 100 µg Dose | 300 µg Dose |
|---|
| 5 mg | 1 mL | 5 mg/mL | 2 units (0.02 mL) | 6 units (0.06 mL) |
| 5 mg | 2 mL | 2.5 mg/mL | 4 units (0.04 mL) | 12 units (0.12 mL) |
| 10 mg | 2 mL | 5 mg/mL | 2 units (0.02 mL) | 6 units (0.06 mL) |
- Reconstitution (SubQ/IN) — Bacteriostatic water down the vial wall at 45°, swirl gently, do not shake.
- Oral administration — Because adamantyl conjugation confers oral bioavailability (at least in rodents), some community users dissolve in water and consume orally. Whether this replicates the mouse drinking-water protocol in humans is unvalidated.
- Storage — Lyophilized: −20°C or refrigerated 2–8°C. Reconstituted: 2–8°C, use within 21 days. Do not freeze reconstituted peptide.
- Source verification — Third-party HPLC + mass-spec COAs are the minimum; the adamantyl-linker chemistry is more failure-prone than simple peptide synthesis and a "P21" batch that lacks the adamantyl group is functionally just an 8-mer peptide with no CNS penetration.
- Inspection — Reconstituted solution should be clear and colorless; discard if cloudy or particulates present.
→ Use the Kalios Peptide Calculator for exact syringe units
Side Effects & Risks
Important
p21 has zero published human trials and no IND. Safety rests entirely on Iqbal-lab rodent work. Ask your provider about any nootropic self-experimentation before ordering.
There is no human safety data. The following captures the best-available safety extrapolation from preclinical studies and mechanistic considerations.
- Unknown human safety profile — The single most important item on this list. No MTD, no adverse-event pattern, no pharmacovigilance signal.
- Preclinical tolerability — Chronic oral administration for several months in mice and cynomolgus monkeys has not produced observable toxicity, weight loss, inflammatory signal, or organ pathology at therapeutic doses.
- Injection site reactions — Expected with any SubQ peptide; no specific data.
- Theoretical seizure risk — Intense BDNF elevation and neurogenesis amplification could theoretically lower seizure threshold or destabilize established memory circuits. No preclinical seizure signal has been reported.
- Theoretical cancer risk — BDNF and neurotrophic signaling can support survival and proliferation of neuroblastoma, medulloblastoma, and glioma cell lines. Individuals with current or prior CNS malignancy should avoid neurotrophic-upregulating research compounds.
- Mood effects — BDNF upregulation is an antidepressant mechanism (shared with SSRIs, ketamine, ECT); in principle mood-positive, but individual variability exists.
- Anti-drug antibody risk — The adamantyl-peptide structure is not a standard immunogen; hypothetical immune response to chronic dosing is uncharacterized.
- Drug interactions — Unknown. Caution with other BDNF-modulating interventions (SSRIs, ketamine, ECT) where additive signaling is theoretically possible.
- Sourcing risk — Adamantyl-linker chemistry is the most failure-prone part of synthesis; poor-quality "P21" may be an 8-mer peptide without CNS penetration — effectively inactive rather than harmful.
- Pregnancy / lactation — No data; avoid.
- WADA status — Not specifically listed. Given narrow use-case footprint, unlikely to become a doping target.
Bloodwork & Monitoring
Monitoring for an unvalidated preclinical compound should emphasize baseline characterization and structured cognitive/behavioral tracking because biochemical surrogates are limited.
- Structured cognitive testing — The most relevant outcome. Baseline and post-protocol assessment using standardized digital cognitive batteries (Cambridge Brain Sciences, CANTAB, NIH Toolbox) plus paper instruments (MoCA, Trail Making A/B, digit span, verbal fluency). Subjective self-report is unreliable for subtle cognitive effects.
- Serum BDNF — Peripheral serum BDNF is an imperfect proxy for brain BDNF but is the most practical biomarker. Trending values pre- and on-treatment can provide indirect evidence of target engagement.
- Comprehensive metabolic panel — Baseline liver and kidney function.
- CBC with differential — Baseline and periodic; any new research peptide warrants basic hematologic surveillance.
- Mood and sleep tracking — Structured instruments (PHQ-9 depression, GAD-7 anxiety, PSQI sleep, ISI insomnia) to detect both benefits and adverse mood shifts from BDNF modulation.
- Seizure surveillance — In anyone with history of seizures or seizure-risk medications, EEG at clinician discretion.
- Dermatologic and oncologic screening — Standard age-appropriate cancer screening prior to and during chronic use.
- Thyroid function (TSH, free T4) — Rule out hypothyroid cognitive symptoms that could confound P21-response assessment.
- B12, folate, homocysteine — Common cognitive-relevant deficiencies; correct before assessing P21 response.
Practical User Notes
Read This First
P21 has never been administered to humans in a published clinical trial. Off-label use is effectively solo Phase 1 self-experimentation. The notes below describe how community users approach the compound; they are informational, not medical guidance.
- Source quality is the largest single variable — Adamantyl-peptide conjugation chemistry is more failure-prone than simple peptide synthesis. A batch missing the adamantyl group is functionally just an 8-mer peptide with no CNS penetration. Third-party HPLC and mass-spec COAs are the operational floor; lot-specific verification is preferred.
- Start low; expect slow response — Neurogenesis and BDNF elevation are slow processes. Short courses (days) are unlikely to produce meaningful outcomes. Plan for 8–12 week protocols at minimum if pursuing the neurogenesis endpoint.
- Baseline cognitive testing before you start — Subjective report is unreliable for gradual cognitive effects. Digital batteries (Cambridge Brain Sciences, CANTAB, NIH Toolbox) establish a personal reference for before/after comparison.
- Foundation first, peptides second — Sleep, aerobic exercise, resistance training, omega-3 intake, and B-vitamin status are all high-leverage inputs to adult neurogenesis. P21 is a polish on top of optimized foundations, not a rescue for chronic sleep debt or sedentary lifestyle.
- Morning dosing preferred — If using for cognitive/alertness applications. Some users report mild sleep disruption with late-day dosing.
- Track mood and sleep — BDNF elevation can shift mood positively; some users report vivid dreaming or sleep architecture changes. PHQ-9 / GAD-7 / PSQI give structured tracking.
- Cycling is prudent — Given the absence of chronic-use human safety data, 8–12 week protocols with a washout period are more conservative than indefinite daily use.
- Stop if anything unusual happens — New seizure activity, persistent mood disturbance, new headaches, visual changes — stop and evaluate. Off-label use means no pharmacovigilance infrastructure.
- Cancer screening hygiene — Age-appropriate oncologic screening before starting any chronic BDNF/neurotrophic-upregulating compound. Avoid in anyone with active or prior CNS malignancy.
- Realistic expectations — If a neurotrophic/neurogenesis compound works, the signal is subtle — slightly clearer thinking, slightly better memory consolidation over weeks. Anyone expecting a stimulant-like cognitive effect will be disappointed; anyone dismissing subtle effects as placebo will miss real signal.
Commonly Stacked With
Semax — Dual Neurotrophic Stack
Semax drives BDNF elevation via intranasal ACTH(4-7)-derived MC4R-adjacent signaling. P21 drives BDNF via CNTF-pathway mimicry. These are mechanistically distinct inputs into the same downstream neurotrophic target. Popular nootropic combination in community protocols; no clinical safety validation.
Dihexa — Neuroplasticity Stack
Dihexa potentiates HGF/c-Met signaling — a distinct neurotrophic pathway. Layered with P21, this provides multi-pathway plasticity drive. Aggressive, speculative, and entirely unvalidated in humans for the combination.
Cerebrolysin delivers a mixed brain-peptide hydrolysate with broad neurotrophic mimicry (NGF, BDNF, GDNF, CNTF-overlapping). Layering P21 with Cerebrolysin courses is used in aggressive neurorehabilitation and cognitive-recovery contexts. No controlled data for the combination.
Aerobic exercise
Exercise is the best-evidenced BDNF-elevating intervention known. P21's mechanism is additive to, not substitutive for, the exercise-BDNF signal. Combining an exercise program with P21 is mechanistically coherent; using P21 to substitute for a sedentary lifestyle is not.
Omega-3 (DHA-dominant, 2–3 g/day)
DHA is a structural membrane lipid critical for synaptic function and neurogenesis; complementary foundation for any BDNF-upregulating intervention.
→ Check compound compatibility in the Stack Builder
Regulatory Status
Current Status — April 2026
P21 is not FDA-approved for any indication. There is no active IND application or published Phase 1 data as of April 2026. The molecule remains a preclinical research compound developed by the Iqbal laboratory at NYSIBR over the period 2010–2023.
P21 is not on the FDA Category 2 Bulk Drug Substances list and is not affected by HHS Secretary Robert F. Kennedy Jr.'s February 2026 reclassification announcement. US 503A/503B compounding pharmacies cannot legally compound P21 because there is no FDA-approved reference product.
P21 is not specifically named on the WADA Prohibited List. The compound's narrow neurotrophic use case and absence of known performance-enhancement signal make WADA-listing unlikely in the near term.
Supply is exclusively through research-chemical vendors. Adamantyl-peptide synthesis quality varies; purity verification is particularly important for this compound.
Cost & Access
P21 (P021) is not approved for human use in the United States, the EU, or any major regulatory jurisdiction. It is available exclusively through research-chemical suppliers for laboratory research purposes only. US compounding pharmacies cannot legally compound P21 under current FDA rules — there is no FDA-approved reference product.
Research-grade P21 is supplied by a small number of specialty vendors as lyophilized powder at typical vial sizes of 5 mg or 10 mg. Because adamantyl-peptide synthesis is more demanding than simple peptide synthesis, batch-to-batch variability in conjugation efficiency has been reported; third-party HPLC and mass-spec verification is the operational floor for product identity.
P21 is not currently among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 2026 Category 2 reclassification announcement. Without a sponsor advancing the molecule through the NDA/IND pathway — and no such program has been publicly announced — P21 is likely to remain a research-only compound for the foreseeable future.
Estimated availability as of April 2026. Actual costs vary by provider, location, and prescription status. Kalios does not sell compounds.
Related Compounds
People researching p21 often also look at these:
Tuftsin-derived anxiolytic and nootropic peptide. Modulates GABA and serotonin systems.
Mitochondrial-encoded 24-amino-acid peptide with neuroprotective and metabolic roles.
N-acetylated semax variant with extended half-life and cleaner intranasal bioavailability.
Key References
- Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, Grundke-Iqbal I. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Lett. 2010;584(15):3359-3365. PMID: 20638986. (Original P21 design and proof-of-concept paper.)
- Bolognin S, Blanchard J, Wang X, Basurto-Islas G, Tung YC, Kohlbrenner E, Grundke-Iqbal I, Iqbal K. An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol. 2012;123(1):133-151. PMID: 22454023.
- Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014;71:110-130. PMID: 25046994.
- Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener. 2016;11(1):50. PMID: 27400670.
- Blanchard J, Wanka L, Tung YC, Cárdenas-Aguayo Mdel C, LaFerla FM, Iqbal K, Grundke-Iqbal I. Pharmacokinetics and efficacy of P021 in a novel mouse model of Alzheimer's disease. Drug Des Devel Ther. 2014;8:711-717. PMID: 25028537.
- Kazim SF, Blanchard J, Bianchi R, Iqbal K. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome. Sci Rep. 2017;7:45561. PMID: 28368026.
- Baazaoui N, Iqbal K. A Novel Therapeutic Approach to Treat Alzheimer's Disease by Neurotrophic Support During the Period of Synaptic Compensation. J Alzheimers Dis. 2018;62(3):1211-1218. PMID: 29526843.
- Kazim SF, Iqbal K. Chronic intermittent fasting reverses cognitive impairment in aged mice. Neurobiol Aging. 2017.
- Baazaoui N, Iqbal K. Prevention of amyloid-β and tau pathologies, associated neurodegeneration, and cognitive deficit by early treatment with a neurotrophic compound. J Alzheimers Dis. 2017;58(1):215-230. PMID: 28527206.
- Khatoon S, Chalbot S, Bolognin S, Puoliväli J, Iqbal K. Elevated tau level in aged rat cerebrospinal fluid reduced by treatment with a neurotrophic compound. J Alzheimers Dis. 2015;47(3):557-564. PMID: 26401700.
- Chohan MO, Li B, Blanchard J, Tung YC, Heaney AT, Rabe A, Iqbal K, Grundke-Iqbal I. Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiol Aging. 2011;32(8):1420-1434. PMID: 19767127.
- Iqbal K, Liu F, Gong CX. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;12(1):15-27. PMID: 26635213. (Parent-context tau review.)
- Kazim SF, Sharma A, Saroja SR, Seo JH, Larson CS, Ramakrishnan A, Wang M, Blitzer RD, Shen L, Peña CJ, Gleason AL, Iqbal K, Nestler EJ. Chronic intermittent fasting supports neurotrophic adaptation. Neurobiol Dis. 2022.
- Sarkar B, Kumar D, Sasmal D, Mukhopadhyay K. CNTF-pathway–mimetic small molecules: mechanistic overview. Curr Alzheimer Res. 2021. (Independent review of CNTF-mimetic programs.)
- Fumagalli F, Racagni G, Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimer's disease? Pharmacogenomics J. 2006;6(1):8-15. PMID: 16302015. (Foundational context for BDNF-elevation as AD strategy.)
Last updated: April 2026 | Profile authored by Kalios Peptides research team